NYTimes: Paxlovid May Reduce Risk of Long Covid in Eligible Patients, Study Finds

Recent findings suggest that taking Paxlovid among those who are eligible for the drug both decreases the risk of hospitalization, as well as lowers the chances of long covid. The results of the study open the door to more questions about Paxlovid’s efficacy, including if it can have these same effects in younger people, and those without medical conditions. However, doctors still acknowledge the possibility for “Paxlovid rebound”, which refers to a return of symptoms or positive result shortly after the first bout. What makes doctors optimistic is that the results of this study show benefits for patients in the acute phase, or when they have a current COVID infection, and the post-acute phase, when they are at risk of long covid symptoms. To read the full article, click here. To read more about COVID-19, click here.